Not Yet Recruiting PHASE2/PHASE3 INTERVENTIONAL 2-arm
NCT07134218
Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer
A National Multicenter, Prospective, Randomized Controlled Study of Serplulimab Injection Combined With Bevacizumab to Improve the Complete Response Rate of Neoadjuvant Therapy for Locally Advanced Stage Intermediate and Low Rectal Cancer
Sponsor: Changhai Hospital
Conditions
Rectal Cancer
Interventions
neoadjuvant chemoradiation therapy serplulimab、bevacizumab
Updated 1 time since 2025 Last updated: Aug 20, 2025 Started: Oct 31, 2025 Primary completion: Oct 31, 2027 Completion: Oct 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07134218, this PHASE2/PHASE3 trial focuses on Rectal Cancer and remains actively recruiting participants. Sponsored by Changhai Hospital, it has been updated 1 time since 2025, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2/PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Changhai Hospital
Data source: Changhai Hospital
For direct contact, visit the study record on ClinicalTrials.gov .